T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 20, Issue 2, 2003, Pages 110-117

  Planck, Anders ^a,b   Katchar, Kianoosh ^a   Eklund, Anders ^a   Gripenbäck, Sofia ^a   Grunewald, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE   (Sweden)

Author keywords

Bronchoalveolar lavage fluid; HLA class II; Lymphocyte activation; Sarcoidosis; T regulatory cells; T lymphocytes

Indexed keywords

CD69 ANTIGEN; HLA DR ANTIGEN; HLA DR17 ANTIGEN; INTERLEUKIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG LAVAGE; MALE; PRIORITY JOURNAL; SARCOIDOSIS; T LYMPHOCYTE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; FEMALE; HEALTH STATUS; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SARCOIDOSIS;

EID: 0038265013     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hunninghake GW, Costabel U, Ando M, et al: ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
2. Newman LS, Rose CS, Maier LA: Sarcoidosis. N Engl J Med 1997; 336: 1224-34.
3. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J: HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156: 1601-5.
4. Planck A, Eklund A, Yamaguchi E, Grunewald J: Angiotensin-converting enzyme gene polymorphism in relation to HLA-DR in sarcoidosis. J Intern Med 2002; 251: 217-22.
5. Grunewald J, Olerup O, Persson U, Ohm MB, Wigzell H, Eklund A: T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci USA 1994; 91: 4965-9.
6. Planck A, Eklund A, Grunewald J: Markers of activity in clinically recovered human leukocyte antigen-DR 17-positive sarcoidosis patients. Eur Respir J 2003; 21: 52-7.
7. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-53.
8. brishtCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003; 33: 215-23.
9. Winterbauer RH, Lammert J, Selland M, Wu R, Corley D, Springmeyer SC: Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104: 352-61.
10. Eklund A, Blaschke E: Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis. Thorax 1986; 41: 629-34.
11. Katchar K, Wahlstrom J, Eklund A, Grunewald J: Highly activated T-cell receptor AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis. Am J Respir Crit Care Med 2001; 163: 1540-5.
12. Muller-Quernheim J, Kronke M, Strausz J, Schykowski M, Ferlinz R: Interleukin-2 receptor gene expression by bronchoalveolar lavage lymphocytes in pulmonary sarcoidosis. Am Rev Respir Dis 1989; 140: 82-8.
13. Saltini C, Spurzem JR, Lee JJ, Pinkston P, Crystal RG: Spontaneous release of interleukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset. J Clin Invest 1986; 77: 1962-70.
14. Semenzato G, Agostini C, Trentin L, et al: Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients. Clin Exp Immunol 1984; 57: 331-7.
15. Muller-Quernheim J: Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998; 12: 716-38.
16. Sakaguchi S. Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-64.
17. Read S, Mauze S, Asseman C, Bean A, Coffman R, Powrie F: CD38+ CD45RB(low) CD4+ T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 1998; 28: 3435-47.
18. Lepault F, Gagnerault MC: Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 2000; 164: 240-7.
19. Groux H, Powrie F: Regulatory T cells and inflammatory bowel disease. Immunol Today 1999; 20; 442-5.
20. Hori S, Carvalho TL, Demengeot J; CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Immunol 2002; 32: 1282-91.
21. Levings MK, Sangregorio R, Roncarolo MG: Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295-302.
22. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G: Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-10.
23. Hol BE, Hintzen RQ, Van Lier RA, Alberts C, Out TA, Jansen HM: Soluble and cellular markers of T cell activation in patients with pulmonary sarcoidosis. Am Rev Respir Dis 1993; 148: 643-9.
24. Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S: Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 2000; 12: 1145-55.
25. Hunninghake GW, Crystal RG: Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981; 305; 429-34.
26. Konishi K, Moller DR, Saltini C, Kirby M, Crystal RG: Spontaneous expression of the interleukin 2 receptor gene and presence of functional interleukin 2 receptors on T lymphocytes in the blood of individuals with active pulmonary sarcoidosis. J Clin Invest 1988; 82: 775-81.